Genmab (via ProfoundBio acquisition)

Copenhagen, Denmark

ADC Monoclonal Antibody Bispecific Antibody

Program data pending ClinicalTrials.gov matching

57.5

Signal Score

○ FDA Inspections ○ Clinical Trials ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: Genmab (via ProfoundBio acquisition)

Signal Score: 57.5/100
Quality Compliance: Assessment pending
Headquarters: Copenhagen, Denmark
Modalities: ADC, Monoclonal Antibody, Bispecific Antibody
Active Programs: No ClinicalTrials.gov matches confirmed
Data Sources: FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By: CDMO Signal — independent CDMO intelligence platform

About Genmab (via ProfoundBio acquisition)

Auto-created by AI matchmaker. Data verification pending.

Signal Score & Pillar Breakdown

Quality Compliance —

No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.

FDA InspectionsNo US records on file

No FDA inspection records found for this manufacturer

Quality score requires FDA inspection data

Operations —

No ClinicalTrials.gov facility matches confirmed for this manufacturer.

Programs — no verified data

Sponsors— no verified data

ModalitiesADC, Monoclonal Antibody, Bispecific Antibody

No clinical trial matches found for this manufacturer

Operational score requires ClinicalTrials.gov data

Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.

Financial Stability

Profile-based financial assessment

SEC FilingsPrivate company

Private company

Financial assessment: 60.0/100

Capacity

Profile-based capacity assessment

Manufacturing site information being gathered

Modalities: ADC, Monoclonal Antibody, Bispecific Antibody

Capacity assessment: 55.0/100

Frequently Asked Questions About Genmab (via ProfoundBio acquisition)

What is Genmab (via ProfoundBio acquisition)'s CDMO Signal Score?

Genmab (via ProfoundBio acquisition) has a Signal Score of 58/100, based on quality, operations, financial stability, and capacity data.

Evaluating Genmab (via ProfoundBio acquisition) for a manufacturing program?

Use the free AI matchmaker to compare Genmab (via ProfoundBio acquisition) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.

Find & compare CDMOs →

Represent this organization? Contact us to verify or update this profile.

See all CDMOs in:

ADC CDMOs →